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Abstract
Introduction: Malaria prevention and iron supplementation are associated with improved maternal and infant outcomes.
However, evidence from studies in children suggests iron may adversely modify the risk of malaria. We reviewed the
evidence in pregnancy of the association between malaria and markers of iron status, iron supplementation or parenteral
treatment.
Methods and Findings: We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, the Global
Health Library, and the Malaria in Pregnancy library to identify studies that investigated the association between iron status,
iron treatment or supplementation during pregnancy and malaria. Thirty one studies contributed to the analysis; 3
experimental and 28 observational studies. Iron supplementation was not associated with an increased risk of P. falciparum
malaria during pregnancy or delivery in Africa (summary Relative Risk = 0.89, 95% Confidence Interval (CI) 0.66–1.20,
I2 = 78.8%, 5 studies). One study in Asia reported an increased risk of P. vivax within 30 days of iron supplementation (e.g.
adjusted Hazard Ratio = 1.75, 95% CI 1.14–2.70 for 1–15 days), but not after 60 days. Iron deficiency (based on ferritin and C-
reactive protein) was associated with lower odds for malaria infection (summary Odds Ratio = 0.35, 0.24–0.51, I2 = 59.2%, 5
studies). With the exception of the acute phase protein ferritin, biomarkers of iron deficiency were generally not associated
with malaria infection.
Conclusions: Iron supplementation was associated with a temporal increase in P vivax, but not with an increased risk of P.
falciparum; however, data are insufficient to rule out the potential for an increased risk of P. falciparum. Iron deficiency was
associated with a decreased malaria risk in pregnancy only when measured with ferritin. Until there is more evidence, it is
prudent to provide iron in combination with malaria prevention during pregnancy.
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Introduction
Anemia affects the lives of more than 500 million women in
developing countries. The consequences of anemia during
pregnancy include maternal mortality and stillbirth [1–5]. Iron
deficiency is generally regarded as the most common cause of
anemia accounting for an estimated 50% of all anemia worldwide.
Iron deficiency anemia (IDA) is thought to cause an estimated
600,000 perinatal and 100,000 maternal deaths per year globally
[6]. In areas where anemia is highly prevalent, international
guidelines recommend universal iron and folic acid supplementa-
tion throughout pregnancy [7].
A recently updated Cochrane review showed evidence that
pregnant women taking iron supplements reduced their risk on
anemia by 70% (risk ratio [RR] 0.3, 95% confidence interval [CI]
0.19–0.46) and iron-deficiency at term by 57% (RR 0.43, 95% CI
0.27–0.66) [8]. In addition, they were less likely to have low birth
weight newborns (,2500 grams) compared with controls (RR
0.81, 95% CI 0.68–0.97). The mean birth weight was 30.8 grams
greater among infants whose mothers received iron during
pregnancy (95% CI 5.9–55.7 grams), whereas the relationship
between iron supplementation and premature birth (,37 weeks of
gestation; RR 0.88, 95% 0.77–1.01) and neonatal death was not
significant (RR 0.90, 95% CI 0.68–1.19) [8]. It is not clear yet if
supplementation translates into clinical improvements such as
reducing the incidence of puerperal infection or postpartum
hemorrhage. Other benefits of maternal iron supplementation
include improved newborn iron stores which are determined
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through in utero acquisition of iron [9], and these iron stores
remain associated with the infants’ iron status at 9 and 24 months
of age [10,11]. This has important implications given that IDA has
been associated with impaired cognitive and motor development
in children [12,13].
The benefits of maternal iron supplementation in malaria-
endemic areas are less clear. An analysis of 101,636 singleton live-
born infants conducted using data from Demographic and Health
Surveys of 19 malaria-endemic countries in sub-Saharan Africa
found that infants whose mothers received any iron/folic acid
supplements and intermittent preventive treatment with sulfadox-
ine-pyrimethamine (IPTp-SP) for malaria during pregnancy were
less likely to have a neonatal death compared to women who did
not receive either iron/folic acid or malaria prophylaxis (hazard
ratio (HR): 0.76; 95% CI 0.58–0.99) [14]. However, this effect was
not seen among mothers who received only iron/folic acid
supplements or only IPTp-SP. A recent meta-analysis of 32
nationally representative health surveys in sub-Saharan Africa,
confirmed the protective association of malaria prevention (IPTp-
SP and ITNs) with a protective efficacy of 18% on neonatal
mortality (95% CI 4–30%) and of 21% for low birth weight (95%
CI 14–27%) [15].
In summary, malaria prevention and iron supplementation are
each associated with improved maternal and infant outcomes.
However, the benefits of iron supplementation in pregnancy must
be carefully weighed against the possibility of adverse consequenc-
es caused by this intervention in certain settings. Evidence from
several studies among children suggests iron supplementation and
iron status may adversely modify the risk of malaria, complicating
a universal policy of routine iron supplementation in children in
malaria endemic areas [16–19]. However, a Cochrane review of
this topic concluded in the presence of regular malaria surveillance
and appropriate treatment there is no increase in malaria risk
among children [20]. A technical working group on iron and
malaria established by the U.S. National Institute of Child Health
and Human Development recently reviewed the evidence and
concluded, ‘‘The balance of evidence indicates that the adminis-
tration of iron supplements, usually in combination with folic acid,
increases the risk of malarial morbidity when given without
malarial prophylaxis, and in the absence of universal access to
treatment’’ [21].
Despite the universal recommendation for iron supplementation
in many malaria endemic countries, this question has yet to be
examined in pregnancy, thereby creating uncertainty among
public health programs regarding the use of iron supplementation
during pregnancy in malaria endemic areas. To address this gap,
we review the evidence in pregnancy of the association between
the risk of malaria and iron status, iron treatment or iron
supplementation.
Methods
Search Strategy
Studies investigating the association between iron status, iron
treatment or iron supplementation during pregnancy and malaria
risk were identified by searching MEDLINE, EMBASE, the
Cochrane Central Register of Controlled Trials, the Global
Health Library from the World Health Organization (WHO) and
the Malaria in Pregnancy library from their inception to January
2013 inclusive without language restrictions [22]. The search was
limited to human studies and used the following search terms:
(pregnant OR pregnancy OR placental OR placenta OR fetus
OR fetal OR foetus OR foetal) AND (iron OR ferrous OR ferric)
AND (malaria OR parasitemia OR parasitaemia OR paludism
OR plasmodium OR falciparum or vivax). The references of all
identified articles, as well as additional review articles, were
examined to locate additional studies not identified during the
computerized search. Authors of potentially relevant articles were
contacted if their methodology suggested relevant data were
available but not presented in the published manuscript. The study
adhered to the PRISMA statement [23].
Selection
Using the search criteria defined above, 299 publications were
identified. Each manuscript was reviewed by two authors (LS and
AVE) and included if it met the following criteria: (1) study
population included pregnant women; (2) data were available to
assess the association between iron status, iron treatment, or iron
supplementation and malaria; (3) for longitudinal studies and
trials: an appropriate control group was included that did not
receive iron; and (4) iron biomarkers were limited to serum ferritin,
serum iron, serum transferrin, transferrin saturation (TS%),
soluble transferrin receptor (sTfR), total iron binding capacity
(TIBC), and erythrocyte protoporphyrin (EP). Discrepancies
between reviewers were resolved through discussions until
consensus was reached. For articles where it could be assumed
that information was available but not presented in the format
needed (e.g. the study reported on malaria and iron deficiency, but
no data on iron deficiency by malaria status was presented), the
authors were contacted for additional information.
Validity Assessment
Details of the methods used to assess validity are included in the
supplemental appendix. In summary, the Cochrane Collabora-
tion’s tool for assessing the risk of bias among randomized trials
was used to determine the quality of included trials as ‘low’ (high
risk of bias), ‘high’ (low risk of bias), or ‘unclear’ [24]. The
assessment of non-randomized study designs were based on source
population, participant selection, completeness of exposure and
outcome data, appropriate tests, sample size, and measures to
control confounding [25,26]. Quality was classified as low-to-
moderate or good (Supplement 1, Figure S1.1, Figure S1.2 in
File S1).
Data Abstraction
A standardized data abstraction form was used to collect the
following data elements: year of publication, geographic location,
population, design, number of subjects enrolled, malaria ende-
micity, duration, frequency and dose of iron, concurrent malaria
treatment or prevention, incidence or prevalence of malaria
parasitemia or placental malaria infection and biomarkers for iron
status.
Classification of Studies
Studies focusing on iron status, iron treatment, and iron
supplementation were considered separately. Iron status studies
were further stratified into iron deficiency and iron biomarkers
studies. Study design was classified as randomized-controlled trial
(RCT), prospective cohort study, retrospective cohort study, case-
control study, cross-sectional study, or before-after study.
Outcomes
The primary outcomes of interest were peripheral malaria
parasitemia during pregnancy or peripheral or placental malaria
infection at the time of delivery by blood smear. Information from
additional malaria tests were included where available (e.g.
placental histology, polymerase chain reaction).
Association between Malaria and Iron in Pregnancy
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Meta-analysis
Data from studies of iron deficiency status and individual iron
biomarkers were summarized using forest plots and meta-analysis
was conducted where possible. If malaria was assessed by more
than one method, the most common test was utilized for the
pooled analysis to decrease heterogeneity. Iron supplementation
data were transformed into summary risk ratios (RR) and 95%
confidence intervals (CI) estimated as the ratio of the proportion of
women with malaria infection among those receiving and not-
receiving iron supplementation during pregnancy. Available
information in included studies allowed three subgroup analyses:
by HIV status, by duration of iron supplementation, and by sickle
cell genotype. Causes of anemia among HIV-infected pregnant
women, iron status and effect of iron supplementation differ from
HIV-negative pregnant women [27,28].
Iron deficiency data was described as ratio of the odds of
malaria among iron deficient vs. non-deficient pregnant women in
cross-sectional studies and case-control studies. Pooled analyses of
iron deficiency and malaria were stratified by timing of malaria
test (during pregnancy or at delivery) and the definition of iron
deficiency. We used three groups; 1) an iron-deficiency definition
based on ferritin and C-reactive protein (CRP, e.g. ferritin ,
30 ng/mL with CRP,= 8?2 ng/mL or ferritin,70 ng/mL with
CRP.8?2 ng/mL, the most common definition), 2) a definition
based on ferritin alone or in another combination (e.g. sTfR/log
ferritin ratio), and 3) all other definitions that did not use ferritin
(e.g. erythrocyte protoporphyrin). The summary odds ratio (OR)
and 95% CI were computed as the pooled ratio of the odds of
malaria among iron deficient and iron replete women; where
available, adjusted odds ratios were used.
Mean differences (MD) were computed to compare the overall
effect for all individual biomarkers by transforming biomarkers to
the same unit (serum iron, TIBC, sTfR, and TS). Because of
skewed distributions for most of the ferritin data, we used
geometric means for ferritin; studies which did not present
geometric means were transformed and geometric mean differ-
ence and 95% confidence interval calculated using the Taylor
series approximation [29,30]. In addition, the ratios of geometric
means were calculated. Individual biomarkers were not stratified
by type of malaria test due to the similarity in results between
peripheral and placental malaria. All meta-analyses were done
using a DerSimonian and Laird random effects model [31]. The
Cochrane’s chi-squared test for heterogeneity set at a significance
of p,0.10 was evaluated. The extent of heterogeneity was
measured using I2, a measure of the proportion of total variability
explained by heterogeneity; this is expressed as a percentage, with
0–25% indicating no or little heterogeneity [32]. Data were
analyzed using Stata 12.1 (Stata Corporation, College Station,
Figure 1. Flow diagram of study selection. Footnote: *1 study (Kapito-Tembo 2010) appears in categories of iron supplementation and iron
status. **Iron status is further stratified into iron deficiency vs. malaria risk and iron biomarkers vs. malaria risk.
doi:10.1371/journal.pone.0087743.g001
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TX), and Comprehensive Meta analysis (version 2.2.055) was used
for subgroup analysis.
Results
Of 299 published studies identified, 31 met the inclusion criteria
(figure 1). Included studies were from a broad range of geographic
locations and published between 1970 and 2012. Studies were
categorized as those assessing the association between iron
supplementation and malaria risk in pregnancy [33–39],
iron deficiency and malaria risk in pregnancy [34,40–50], iron
biomarkers and malaria risk in pregnancy [40–43,46,47,50–61], or
iron treatment and malaria risk in pregnancy [62,63]. These
included two randomized controlled trials [36,37] and one sub-
group analysis [33] from the main trial [37], two prospective
cohort studies [38,62], one before-after study [39], one retrospec-
tive cohort study [63], six case-control studies [40,47,49,52–54],
and 18 cross-sectional studies (table 1–4) [34,35,41–
46,48,50,51,55–61]. One cross-sectional study was described in
two articles, the original analyzed serum ferritin relative to malaria
infection [57] and the supplemental article considered iron
deficiency status controlling for inflammation relative to malaria
infection [45].
Quality of the Included Studies
The two trials, both published before the more widespread
adoption of the CONSORT guidelines, were assessed as low
quality, mainly because allocation concealment was not described.
Overall, there were ten observational studies among the 25
evaluated which we marked as good quality. None of the
observational studies reported a justification for the sample size
of the study. For 16 studies, the association between iron and
malaria was reported as one of the primary purposes of the
analysis. The lack of a description of methods used to adjust for
potential confounding was the most common deficit in the
reporting of observational studies (15 times, eSupplement 1).
Oral Iron Supplementation and Malaria Risk
P. falciparum malaria. The effect of iron supplementation
on malaria risk in pregnancy was assessed in seven studies which
included the two trials [36,37], the one randomized trial sub-group
analysis [33], one prospective cohort study [38], one before-after
study [39], and two cross-sectional studies [34,35]. The dose and
duration of iron supplementation varied in the studies, as did the
level of malaria endemicity and use of malaria prevention
interventions (table 1).
A meta-analysis was performed among the iron supplementa-
tion studies stratified by timing of malaria test. This analysis
excluded the sub-group analysis from the RCT because these
women were represented in the parent study [33], and the study
using hazard ratios because these data were only presented by
duration of iron supplementation and therefore not comparable to
the other studies [38]. The overall pooled result of iron
supplementation during pregnancy or delivery was not associated
with an increased risk of malaria (RRpooled 0.89, 95% CI 0.66–
1.20; I2 78.8%, figure 2). Stratum specific results also showed no
increase in risk of malaria associated with iron supplementation
during pregnancy (RRpooled 0.58, 95% CI 0.20–1.73; I
2 89.9%) or
at the time of delivery (RRpooled 1.02, 95% CI 0.75–1.39; I
2
73.0%, figure 2). Baseline iron status was not assessed in any of the
studies, so a subgroup analysis among iron-replete and iron
deficient women was not possible.
The results of further sub-group analysis can be seen in the
supplement (File S1). No significant difference was seen by HIV
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status for the association between iron supplementation and the
risk of malaria (p = 0.6 comparing groups by HIV-status, Figure
S2.1 in File S1). Sub-group analyses from the randomized trial
stratifying the data by hemoglobin genotype suggested a possible
difference in placental malaria associated with iron supplemen-
tation by sickle cell genotype, however, this difference was not
statistically significant (Figure S2.2 in File S1). Three studies (two
surveys and a cohort) presented information by duration of iron
supplementation. In a subgroup analysis for the two surveys in
Africa, a duration of iron supplementation of .30 days was
associated with a higher malaria risk (RRpooled 1.42, 95% CI
1?09–1.84; I2 0%, Figure S2.3 in File S1), despite high coverage
of antimalarial prevention [34,35]. In the survey among HIV-
infected women, overall 65% used IPTp, 45% used daily
cotrimoxazole prophylaxis (which has antimalarial activity), and
60% used nets; use of antimalarial prevention was less among
women who did not use iron [34]. In the other survey, 94% of
women used at least one dose of SP, and 23% used nets [35]. By
contrast, the cohort study conducted on the Thai-Burmese
border suggested no increase in risk of first episode of P. falciparum
associated with iron supplementation up to 60 days (e.g. 1–15
days iron supplementation: Adjusted Hazard Ratio (aHR) 1.30,
95% CI 0.67–2.50, p = 0.4, table 5). Longer supplementation was
even associated with a reduced risk (aHR iron supplementation
.60 days: 0.37, 95% CI 0.17–0.77, p = 0.009, table 5). No
antimalarial prophylaxis was used in this cohort and there was no
information on net use but women were screened for malaria
weekly and treated promptly [38].
P. vivaxmalaria. In the single study from Asia that assessed
the association between iron supplementation and P. vivax
malaria, there was an increase in risk of first episode of P. vixax
parasitemia associated with iron supplementation, but only
during the first 30 days (for 1–15 days aHR 1.75, 95% CI
1.14–2.70, p = 0.009) and 16–30 days (aHR 1.70, 95% CI 1.10–
2.60, p = 0.01), after which the effect declined, and reversed for
women who had taken iron supplementation for .60 days (aHR
0.67, 95% CI 0.40–1.02, p = 0.06, table 5) [38].
Parenteral Iron Treatment and Malaria Risk
Associations between parenteral iron treatment among severe-
ly anemic pregnant women and malaria risk were evaluated in
one retrospective and one prospective study (table 6) [62,63]. The
retrospective study compared malaria during the post-natal
period between severely anemic pregnant women treated during
pregnancy with a single intravenous dose of 1750 mg of iron to
women without anemia. A marked increase in the odds of
postnatal malaria was observed among primiparous women (OR
5.5, 95% CI 2.2–13.5) whereas this association was not seen
among multiparious women (OR 1.1, 95% CI 0.73–1.70) [63].
The prospective cohort study assessed the incidence of local and
general reactions to total dose infusion of iron dextran among
four groups of pregnant women: A: iron only; B: iron+
antihistamine; C: iron+chloroquine; D: iron+antihistamine+
chloroquine. However, they only assessed the presence of malaria
following infusion among those women with general reactions.
Among women with general reactions, those not concurrently
receiving chloroquine with their iron infusion were more likely to
have malaria parasitemia after the infusion compared to women
who did receive concurrent chloroquine (28.2% vs. 0%,
respectively; p = 0.17) [62]. Indications, timing of iron treatment
and malaria assessment between the studies were too dissimilar to
perform a pooled analysis.
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Figure 2. Plasmodium falciparum by blood smear among iron-supplemented and non-supplemented pregnant women by timing of
malaria test. Footnote: AM: antimalarials used (either IPTp or cotrimoxazole). CI: confidence interval. G1: primigravidae. G2+: Multigravidae. HIV(+):
HIV-positive. IPTp2: intermittent preventive treatment with 2 doses of sulfadoxine-pyrimethamine. *Daily dose of elementary iron. Notes: At delivery:
placental blood smear for Ndyomugyenyi 2000 and van Eijk 2007, and peripheral blood smear for Mwapasa 2004. The weight for each study is
indicated as a grey block around the risk estimate. Subgroup analyses and additional data are included in eSupplement 3.
doi:10.1371/journal.pone.0087743.g002
Table 5. Summary of study outcomes – Iron Supplementation vs. Malaria Risk.
Author, Year Study Design HIV Status
Type & Timing of
malaria test Exposure
Comparison
to exposure
Risk estimate
(95% CI)
Outcome: First malaria episode during follow-up – Plasmodium vivax
Iron+FA 1–15 d No FA+ Iron use aHR1 1.75 (1.14, 2.70)
Nacher 2003 [38] Prospective Cohort All Peripheral BS during
pregnancy
Iron+FA 16–30d No FA+ Iron use aHR1 1.70 (1.10, 2.60)
Iron+FA 31–60d No FA+ Iron use aHR1 1.30 (0.94, 1.80)
Iron+FA .60d No FA+ Iron use aHR1 0.67 (0.40, 1.02)
Outcome: First malaria episode during follow-up – Plasmodium falciparum
Iron+FA 1–15 d No FA+ Iron use aHR1 1.30 (0.67, 2.50)
Nacher 2003 [38] Prospective Cohort All Peripheral BS during
pregnancy
Iron+FA 16–30d No FA+ Iron use aHR1 0.90 (0.40, 2.10)
Iron+FA 31–60d No FA+ Iron use aHR1 1.40 (0.80, 2.40)
Iron+FA .60d No FA+ Iron use aHR1 0.37 (0.17, 0.77)
aHR: adjusted Hazard Ratio. BS: Blood slide. FA: Folic Acid.
1Adjusted for Plasmodium falciparum or Plasmodium vivax, gravidity, age, estimated gestational age, past mean hematocrit.
doi:10.1371/journal.pone.0087743.t005
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Table 6. Summary of study outcomes – Iron Treatment vs. Malaria Risk.
Author, Year Study Design Outcome
Exposure
% (n)
Comparison
to exposure
% (n)
Risk estimate
(95% CI)
or p-value
Oppenheimer,
1986 [63]
Retrospective
Cohort
Postnatal malaria- primigravida Total Dose Iron Infusion
20?4% (11/54)
No Total Dose Iron
Infusion 4?5% (3/67)
RR 4?55 (1?34–15?49) OR 5?46
(1?44, 20?7)
Postnatal malaria- multigravida Total Dose Iron Infusion
8?4% (8/95)
No Total Dose Iron
Infusion 7?6% (14/184)
RR 1?11 (0?48–2?54) OR 1?12
(0?45, 2?76)
Byles, 1970 [62] Prospective
Cohort
Generalized reactions after total
dose iron infusion
Total dose iron+
Concurrent CQ 1?5%
(7/462)
Total dose iron+No
concurrent CQ 8?6%
(39/455)
OR 0?16 (0?07–0?37) RR 0?18
(0?08–0?39)
PF parasitemia present among
participants with generalized reactions
after total dose iron infusion
Total dose iron+
Concurrent CQ 0?0%
(0/7)
Total dose iron+No
concurrent CQ 28?2%
(11/39)
p = 0?17
CI: confidence interval. CQ: chloroquine. OR: odds ratio. PF: Plasmodium falciparum. RR: risk ratio.
doi:10.1371/journal.pone.0087743.t006
Figure 3. Malaria parasitemia by blood smear among iron deficient and non-deficient participants, by definition of iron deficiency
during pregnancy. Footnote: CI: confidence interval. CRP: C-Reactive Protein. EP: Erthyrocyte protoporphyrin. Hb: hemoglobin. *Use of adjusted
odds ratios: Kapito-Tembo 2010: odds ratio adjusted for CD4 count, gravidity, and intestinal infections, Dreyfuss: odds ratio adjusted for hookworm
infection, serum retinol and trimester of pregnancy. **Iron deficiency definition: Ferritin ,30 ng/mL & CRP,= 8.2 ng/mL or ferritin ,70 ng/mL &
CRP.8.2 ng/mL. The weight for each study is indicated as a grey block around the risk estimate. For Dreyfuss 2000, malaria parasitemia was limited
to P. vivax in Asia. All other studies were conducted in Africa where P. falciparum is the predominant species.
doi:10.1371/journal.pone.0087743.g003
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Iron Deficiency and Malaria Risk
The effect of iron deficiency on malaria risk in pregnancy was
assessed in 12 studies including three case-control studies
[40,47,49], and nine cross-sectional studies (table 2) [34,41–
46,48,50]. Among these studies, five considered evidence of
malaria at the time of delivery [40,44,48–50], six considered
malaria at the time of enrollment [34,41–43,45,47], and one did
not specify when iron deficiency was assessed [46]. Seven of these
12 studies used the same definitions of iron deficiency (serum
ferritin ,30 ng/mL with CRP,= 8.2 ng/mL or serum ferritin ,
70 ng/mL with CRP.8.2 ng/mL), and pooled analysis showed
an overall decreased odds for peripheral parasitemia in pregnancy
(ORpooled 0.35, 95% CI 0.24–0.51; I
2 59.2%, five studies, figure 3)
associated with iron deficiency, but this was not significant for
placental malaria (ORpooled 0.34, 95% CI 0.11–1.10; I
2 75?8%,
two studies, figure 4). Other definitions using ferritin tended to
show similar results with decreased odds of malaria among iron-
deficient women (figure 3 and 4); however, where definitions were
used which did not include ferritin, no overall effect was seen
(ORpooled for malaria in pregnancy: 1.65, 95% CI 0.88–3.09, I
2
59.6%, three studies, figure 3). Additional iron deficiency
definitions and malaria outcomes which could not be included
because of overlap of studies are listed in the supplement File S1. A
subgroup analysis was conducted by gravidity which indicated that
the association between malaria parasitaemia and markers of iron
status were similar among the different gravidae groups (Figure
S3.2 in File S1).
Iron Biomarkers and Malaria Risk
Iron biomarkers evaluated included serum ferritin, serum iron,
total iron binding capacity, soluble transferrin receptor, transferrin
saturation (as %) and serum transferrin (figure 4). Studies which
could not be included in forest plots because of insufficient
information are presented in Table 7. The pooled analysis of
serum ferritin was conducted among ten studies for which
geometric mean values were provided or could be calculated
and showed that the concentration of serum ferritin was higher
among malaria infected pregnant women compared to those who
were uninfected (geometric mean differencepooled 0.53, 95% CI
0.44–0.62, I2 90.8%, figure 5), which corresponds to ferritin levels
Figure 4. Malaria parasitemia among iron deficient and non-deficient participants, by definition of iron deficiency at the time of
delivery. Footnote: BS: bloodsmear. CI: confidence interval. CRP: C-reactive protein. EP: Erthyrocyte protoporphyrin. Hb: hemoglobin. sTfR: Soluble
transferrin receptor. *Adjusted odds ratios used: Kabyemela 2008: odds ratio adjusted for gravidity. Senga 2011: odds ratio adjusted for gravidity, age,
and blood group. Placental histology in Senga 2011: active infection defined by acute or chronic infection (parasites alone, or parasites in the
presence of haemozoin). No placental infection defined by the absence of parasites and haemozoin. ** Ferritin 30/CRP 8.3: Ferritin ,30 ng/mL &
CRP,=8.2 ng/mL or ferritin ,70 ng/mL & CRP.8.2 ng/mL. The weight for each study is indicated as a grey block around the risk estimate.
doi:10.1371/journal.pone.0087743.g004
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Figure 5. Geometric mean difference in ferritin among pregnant women infected with malaria compared to pregnant women
without malaria. Footnote: CI: confidence interval. SD: standard deviation. *Van Santen 2011 and Massawe 2002: study population primigravidae.
Abrams 2005 and Ouedraogo 2012: study population HIV(-) women. The weight for each study is indicated as a grey block around the risk estimate.
For Dreyfuss 2000, the malaria parasitemia was limited to P. Vivax in Asia. All other studies were conducted in Africa where P. falciparum is the
predominant species.
doi:10.1371/journal.pone.0087743.g005
Table 7. Summary of study outcomes – Iron biomarkers vs. malaria risk, and outcomes not presented in forest plot.
Author, Year
Study
Design
Biomarker
(Outcome)
Exposure
% (n or IQR)
Comparison to exposure
% Outcome (n or IQR) p-value
Engmann 2008
[41]
Cross-
sectional
Serum ferritin (mg/L) Peripheral parasitemia at enrollment Median
91 (IQR: 33, 157)
No peripheral parasitemia at enrollment
Median 33 (IQR: 20, 50)
Not
provided
Matteelli 1994
[42]
Cross-
sectional
Serum ferritin (ng/mL) Peripheral parasitemia at delivery Mean 65.7
(n = 106)
No peripheral parasitemia at delivery
Mean 36.5 (n = 98)
p = 0.002
Ndyomugyenyi
2008 [61]
Cross-
sectional
Serum ferritin (mg/L) Peripheral parasitemia at enrollment
(Means not available)
No peripheral parasitemia at enrollment
(means not available)
p = 0.007
Saad 2012 [52] Case-
control
Serum ferritin (mg/L) Peripheral parasitemia at enrollment
(Uncomplicated malaria) Median 63.3
(IQR: 30.5, 113.2)
No peripheral parasitemia at enrollment
Median 34.4 (IQR: 7.9, 60.3)
p = 0.041
Serum ferritin (mg/L) Peripheral parasitemia at enrollment
(Severe malaria) Median 78.6
(IQR: 44.1, 148.9)
No peripheral parasitemia at enrollment
Median 34.4 (IQR: 7.9, 60.3)
p = 0.002
Dreyfuss
2000 [46]
Cross-
sectional
Erythrocyte Protoporhyrin
(mmol/mol heme)
Peripheral parasitemia at enrollment
Geometric mean 90 (CI 54, 150) (n = 57)
No peripheral parasitemia at enrollment
Geometric mean 84 (CI 52, 134) (n = 231)
P = 0.3
CI: confidence interval. IQR: Interquartal range.
doi:10.1371/journal.pone.0087743.t007
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being 70% (95% CI 55–86%) higher in women with malaria
compared to those without.
The same pattern was seen in four studies which could not be
included in the meta-analysis (table 7). No significant pooled
differences were detected for serum iron (eight studies), total iron
binding capacity (five studies), soluble transferrin receptor (four
studies), serum transferrin (three studies), and tranferrin saturation
(four studies), whereby it should be noted that the heterogeneity
was 0% for soluble transferrin receptor and transferrin saturation
(figure 6 and 7).
Discussion
To our knowledge, this systematic review represents the first
effort to assess the association of iron status and use on the risk of
malaria in pregnancy. Pooled analyses of iron deficiency status,
using a definition based on ferritin and adjusting for inflammation
with CRP, indicated pregnant women with iron deficiency had a
reduced risk of malaria infection during pregnancy. However,
pooled analyses from the remaining biomarkers of iron deficiency
were not associated with malaria. Data from randomized and
observational studies did not show an increased risk of P. falciparum
malaria among the participants who received oral iron supple-
mentation, whereas one cohort study in Asia showed an increased
risk of P. vivax in the first 30 days of oral iron (and folate)
supplementation. None of the studies however, assessed the
individual’s baseline iron status which may modify the effect of
iron supplementation on malaria risk, complicating the interpre-
tation of these data. Except for the studies using parenteral iron
treatment, all included studies used oral iron supplementation for
the prevention of iron deficiency anemia during pregnancy; oral
iron was not given for the treatment of established anemia and/or
iron-deficiency in these studies. This difference can be important
because the treatment of anemia in pregnancy recommends using
temporarily higher doses of iron, specific policies for iron dose and
duration vary by country [7].
Only two studies evaluated parenteral treatment with iron
dextran and the study qualities were insufficient to make
conclusions. In addition, new parenteral iron treatment options
using complex iron-polysaccharides are available which may not
have a similar risk profile with regards to infections such as malaria
[64].
Several hypotheses have been provided as to why malaria
infection may be less prevalent among people with iron deficiency.
Figure 6. Mean difference in soluble transferring receptor and serum transferrin among pregnant women infected with malaria
compared to pregnant women without malaria. Footnote: CI: confidence interval. SD: standard deviation. *Van Santen 2011 and Massawe
2002: study population primigravidae. Abrams 2005: study population HIV(-) women. The weight for each study is indicated as a grey block around
the risk estimate. Removal of the study of Eteng 2010, an outlier for Serum Transferrin, gives the following result: Pooled mean difference Serum
Transferrin (g/L): 20.11, 95% CI 20.30 to 0.09, I2 14.8%.
doi:10.1371/journal.pone.0087743.g006
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Iron is vital for the survival of the malaria parasite and the parasite
is unable to thrive in iron-deficient environments [65]. Specifically,
iron deficiency suppresses erythropoiesis, the production of red
blood cells, thereby reducing the opportunity for the parasite to
infect the host [66]. Additionally, some aspects of the host
immunity against malaria may be boosted with iron deficiency.
For example, the host macrophage defense utilizes nitric oxide in
the control of P. falciparum and because iron can down-regulate the
formation of nitric oxide within macrophages [67], iron deficiency
may therefore enable a stronger host-macrophage response.
Evidence from iron chelation studies using desferrioxamine
(DFO) provides support that iron-deficient environments are
unfavorable to foster malaria infections. In one randomized
double-blind placebo cross-over study, DFO among asymptomatic
parasitemic adults was associated with enhanced parasite clear-
ance compared to placebo [68]. Another double-blind randomized
study among children with cerebral malaria showed the median
recovery time from children in deep coma was reduced by half
(and the rate of parasite clearance was improved) when DFO was
added to treatment with quinine compared to the antimalarial
treatment plus placebo [69].
Multiple iron biomarkers have been associated with malaria
infection among various populations. The most widely reported is
serum ferritin, a known acute-phase reactant protein that can
increase in response to underlying infection or inflammation
regardless of underlying iron stores [55,70–76]. Our data confirm
serum ferritin is increased in the presence of malaria infection in
pregnant women. The reported association between malaria and
iron deficiency reported above adjusted for the effect of
inflammation. Results from our pooled analysis did not find
statistically significant associations between the remaining bio-
markers and malaria. These results are in agreement with findings
in the literature among non-pregnant populations where associ-
ations have been inconsistent between malaria and: sTfR
[21,70,72,73,77,78], transferrin [72,73], and transferrin saturation
[72].
Despite the evidence that serum ferritin increases as a result of
pregnancy per se, infection or inflammation, it remains the
international standard for defining iron deficiency [79]. This
creates an inherent challenge to measuring iron deficiency using
cutoffs of serum ferritin in pregnant populations living in malaria
endemic settings (see also Figure S3.1 in File S1). Consensus exists
Figure 7. Mean difference in transferrin saturation, serum iron and total iron binding capacity among pregnant women infected
with malaria compared to pregnant women without malaria. Footnote: CI: confidence interval. SD: standard deviation. *Van Santen 2011:
study population primigravidae. The weight for each study is indicated as a grey block around the risk estimate. Removal of the study of Eteng 2010,
an outlier for Serum Iron and Total Iron Binding Capacity, gives the following results: Pooled mean difference serum iron (mmol/L): 21.13, 22.57 to
0.31, I2 27.3%; Pooled mean difference Total Iron Binding Capacity (mmol/L): 0.13, 20.67 to 0.92, I-squared 0%.
doi:10.1371/journal.pone.0087743.g007
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that serum ferritin should be measured with inflammatory markers
such as C-reactive protein, a1-antichymotrypsin, or a1-acid
glycoprotein; however, agreement has yet to be made on the best
inflammatory markers and their corresponding cutoff values for
defining iron deficiency in the presence of inflammation [80–83].
Other iron biomarkers have been proposed to replace serum
ferritin including sTfR. While it has been suggested sTfR is
unaffected by pregnancy or inflammation [84], evidence of how
pregnancy affects concentrations of sTfR is lacking [79]. The
extent to which sTfR is affected by pregnancy will determine the
appropriateness of using sTfR as a biomarker for detecting iron
deficiency in pregnancy, especially in malaria endemic settings.
While the evidence of iron supplementation related to malaria
risk in pregnancy is not of strong quality, the available data suggest
iron supplementation does not increase the risk of malaria. Among
the seven studies included in this review, only two of them
represented primary data analyses from randomized trials, both of
which failed to see an association between iron supplementation in
pregnancy and malaria risk. No routine medical malaria
prevention was used in these trials among the women included
in this review, and they were conducted before the wide-scale
introduction of insecticide treated nets [36,37]. The same applied
to the study using a before-after design [39].
Prevalence of use of malaria prevention strategies varied greatly
between the two surveys included for iron supplementation, and
these showed the greatest variety in the association between iron
supplementation and malaria [34,35]. One survey reported less
malaria among iron supplemented (HIV-infected) women (figure 2)
[34]; however, it should be noted, that we transformed their data
from odds ratios to risk ratios to be able to combine the results of
the different studies [34]. Kapito-Tembo (2010) reported an odds
ratio of 0.4, 95% CI 0.14–1.12, in multivariable analysis,
comparing iron supplemented vs. not supplemented when
adjusting for age, gravidity, bed net use, socio-economic status,
antenatal visits, IPTp use or cotrimoxazole prophylaxis [34].
The higher risk of malaria among women that used iron for .
30 days in the subgroup analysis (Figure S2.3 in File S1) could
potentially be explained by the association with IPTp [34,35].
Women who use iron for #30 days may be protected by the last
dose of IPTp with SP if this was given at the visit when the iron
supplementation commenced. SP is known to provide four to six
weeks of post-treatment prophylaxis against malaria after which
protective drug levels wane, placing women who continue using
iron at risk until they receive the next dose of SP. In addition, some
women may have initially been iron deficient, but with continued
supplementation, have become iron replete, which may contribute
to development of malaria [18,85]. Among children it has been
suggested that an individual’s baseline iron status may modify the
risk of malaria associated with iron supplementation; e.g. among
iron-deficient persons, iron supplementation may decrease ane-
mia, whereas among iron-replete persons, supplementation may
have no benefits for anemia reduction and only result in an
increased risk for malaria [21]. However, none of the iron
supplementation studies included baseline iron status, although
they all showed either a decrease in anemia (RRpooled 0.79, 95%
CI 0.73–0.85, four studies, I2 31.7%, Figure S5.1 in File S1), or an
improvement in hemoglobin (mean increase 0.79 g/dl, 95% CI
0.64–0.95, three studies, I2 15?6%, Figure S5.2 in File S1). While
direct evidence of risk associated with iron supplementation is
lacking, strong evidence exists that iron supplementation improves
hemoglobin levels and decreases the risk of anemia and improves
newborn iron stores [8,9,86].
This review is subject to several limitations, an examination of
which may inform the design and conduct of future studies of iron
supplementation during pregnancy in malaria endemic areas.
First, the 31 studies identified were widely heterogeneous. Among
the seven studies with data on iron supplementation, the
cumulative dose of iron used and the timing and type of malaria
testing varied as did the study design and methodology reducing
comparability and preventing a pooled analysis across all available
studies. Blood smears used to be the standard for detecting malaria
whereas now rapid diagnostic malaria tests, placental histology,
and polymerase chain reactions are increasingly used, with the
latter two tests having a higher sensitivity in detecting malaria [87].
Furthermore, the Entomological Inoculation Rate (a measure of
malaria transmission in an area) and the prevalence of malaria
varied greatly across these studies, as did the use of malaria
prevention strategies, and the dose and duration of iron
supplementation (table 1, 2, 3, 4). The distribution of biomarkers
was not always normally distributed, and approximations of
geometric means were made for ferritin. Consistency on these
methodological aspects would allow for more accurate synthesis of
the body of literature. The majority of these data are based on
cross-sectional studies which provide evidence of an association
between these factors, but cannot confirm a causal association
between iron deficiency (measured by serum ferritin) and malaria
risk. In addition, the direction of this association between malaria
and iron status is unclear, as iron status may affect the malaria risk,
but malaria infection itself causes an inflammatory response as well
as hemolysis and will affect these measures of iron status. Lastly,
with the exception of three studies, these data represent the risk
associated with Plasmodium falciparum infections in Africa
[38,46,63], and the effect of iron on malaria risk may differ by
species and regions.
Directions for Future Research
While in children in malaria endemic areas there has been
enough evidence of increased risk of morbidity associated with
iron use to result in a more restricted policy in this population,
surprisingly little is known of the risk-benefits in pregnancy and
universal iron supplementation continues to be recommended
during pregnancy. Because the relationship between malaria and
iron status is difficult to disentangle, descriptive studies are not
adequate, and randomized placebo controlled intervention trials
may be the only way to answer the causal relationship between
iron and malaria infection. However, these are costly and there
may be ethical considerations due the need to withhold an
intervention that is policy in most countries and the proven health
benefit of iron supplementation in pregnant women. Using a
clinical trial register, we identified five studies in various stages
which will start to address some of these issues; baseline assessment
of iron status will be important as well as the use of different
definitions of iron deficiency, preferably not all ferritin-based [88–
92].
These data suggest that iron supplementation may be safe in
malaria endemic areas among women concurrently using malaria
prevention strategies such as insecticide treated nets, monthly
IPTp or daily cotrimoxazol (in HIV-infected women). Although
IPTp and insecticide treated nets are currently the main policies to
prevent malaria in pregnant women in sub-Saharan Africa, their
coverage is less than optimal and it would be important to ensure
that individual women receiving iron supplementation are indeed
protected by an insecticide treated net and receive IPTp [93].
Because IPTp with SP is contraindicated in the first trimester, it is
important to ensure that women using iron early in pregnancy are
using an insecticide treated net and are screened for malaria at
each scheduled visit until they can receive IPTp. With some
countries moving towards iron fortification, it will also be prudent
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to understand the potential risk and benefits of additional exposure
to oral iron supplementation that is likely to be continued to be
provided for some time, as part of routine antenatal care.
Conclusion
Our review suggests iron supplementation may be safe during
pregnancy in malaria endemic areas. However, the available data
on iron supplementation in pregnancy and malaria risk are limited
and insufficient to rule out any potential for an increased risk of
malaria in malaria endemic settings. While iron deficiency (based
on a definition with ferritin and CRP) is associated with a marked
decreased risk of malaria in pregnancy, this association was not
present among any of the other biomarkers of iron deficiency.
Therefore, we find the results of iron deficiency and malaria risk to
be inconclusive. Until more data are available from pregnant
women, it would be prudent, based on the available evidence
among children, to recommend that the provision of universal iron
supplementation in pregnant women should always occur in
conjunction with malaria prevention strategies during pregnancy
in malaria endemic areas.
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